HSP90AB1 and psoriasis: NB transdermally treats psoriasis by targeting the epigenetic regulator CTCF (CCCTC‐binding factor), suppressing HSP90AB1 (heat shock protein 90 alpha family class B member 1) transcription, and disrupting the HSP90AB1‐CDC37 (cell division cycle 37) chaperone complex to inactivate its client proteins.